PROCEPT BioRobotics Corp
PRCTdata completeness 100%6 fiscal years on filePROCEPT BioRobotics Corp earns about -49% on invested capital, but has diluted owners by 237% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $34.5M1 | $75M2 | $136.2M3 | $224.5M3 | $308.1M3 |
| Net income | −$59.9M4 | −$87.2M5 | −$105.9M6 | −$91.4M6 | −$95.6M6 |
| Operating cash flow | −$57.3M7 | −$80.4M8 | −$108M9 | −$99.2M9 | −$49M9 |
| Capital expenditure | $592,00010 | $2.65M11 | $25.2M12 | $4.41M12 | $9.36M12 |
| Free cash flow (derived) | −$57.9M7 | −$83M8 | −$133.2M9 | −$103.6M9 | −$58.3M9 |
| Total debt | $100M13 | $102.4M14 | $102.7M15 | $102.9M16 | $103.2M16 |
| Cash & equivalents | $304.3M17 | $221.9M18 | $257.2M19 | $333.7M19 | $286.5M19 |
| Diluted shares | 16.5M | 44.4M | 47.3M | 52.1M | 55.5M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $65.87 of net worth that earned you −$17.21 and generated −$10.5 of cash last year, against $18.59 of debt.
It earned an average -49% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 237% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0001588978-24-000006 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0001588978-25-000007 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001588978-26-000009 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0001588978-24-000006 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001588978-25-000007 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001588978-26-000009 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001588978-24-000006 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001588978-25-000007 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001588978-26-000009 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001588978-24-000006 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0001588978-25-000007 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001588978-26-000009 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0001588978-23-000009 (LongTermDebtNoncurrent)
- 10-K · period ending 2022-12-31 · accession 0001588978-24-000006 (LongTermDebtNoncurrent)
- 10-K · period ending 2023-12-31 · accession 0001588978-25-000007 (LongTermDebtNoncurrent)
- 10-K · period ending 2024-12-31 · accession 0001588978-26-000009 (LongTermDebtNoncurrent)
- 10-K · period ending 2021-12-31 · accession 0001588978-24-000006 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0001588978-25-000007 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001588978-26-000009 (CashAndCashEquivalentsAtCarryingValue)